Scattering-Dominant Contrast Agents for Optical Coherence Tomography
Source abstract
Abstract
We report a scattering-dominant agent that significantly enhances optical coherence tomography (OCT) imaging contrast. Unlike most other gold nanoparticle-based OCT agents, which are absorption-dominant and reduce imaging depth, our agent is based on gold nanocages, which exhibit a surface plasmon resonance (SPR) peak around 780 nm and a scattering cross-section that exceeds the absorption cross-section. The scattering-dominant gold nanocages act as nanosized mirrors that enhance backscattered OCT signals. The synthesis protocol for these nanocages is provided in detail. The optical properties of the gold nanocages were characterized using OCT imaging and further validated with integrating sphere measurements. OCT contrast enhancement was demonstrated through imaging of tissue phantoms containing embedded nanocages, as well as ex vivo imaging of mouse tissues and in vivo imaging of a mouse tumor following intravenous administration of PEGylated gold nanocages. To the best of our knowledge, this is the first demonstration of scattering-dominant OCT contrast agents utilizing structured gold nanocages.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Optical Coherence Tomography Applications · Photoacoustic and Ultrasonic Imaging · Advanced Fluorescence Microscopy Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Biomedical Engineering
Johns Hopkins University
Florida International University
Funding
National Institutes of Health
References (36)
Show source-provided references
1. 10.1126/science.195716910.1126/science.1957169 ↗
2. 10.1021/ja078176p10.1021/ja078176p ↗
3. 10.1016/0301-5629(94)90001-910.1016/0301-5629(94)90001-9 ↗
4. 10.1038/nmat157110.1038/nmat1571 ↗
5. 10.1038/nm146710.1038/nm1467 ↗
6. 10.1364/OL.28.00154610.1364/OL.28.001546 ↗
7. 10.1016/S1076-6332(03)80395-110.1016/S1076-6332(03)80395-1 ↗
8. 10.1364/OL.29.00164710.1364/OL.29.001647 ↗
9. 10.1021/nl070610y10.1021/nl070610y ↗
10. 10.1364/OL.32.00143810.1364/OL.32.001438 ↗
11. 10.1364/OL.30.00304810.1364/OL.30.003048 ↗
12. 10.1021/ja039734c10.1021/ja039734c ↗
13. 10.1021/ja066023g10.1021/ja066023g ↗
14. 10.1021/ja067800f10.1021/ja067800f ↗
15. 10.1021/nl070345g10.1021/nl070345g ↗
16. 10.1021/acs.langmuir.5b0144410.1021/acs.langmuir.5b01444 ↗
17. 10.1021/nn700360310.1021/nn7003603 ↗
18. 10.1021/nl048610a10.1021/nl048610a ↗
19. 10.1021/acsanm.2c0253310.1021/acsanm.2c02533 ↗
20. 10.1021/nl062969c10.1021/nl062969c ↗
21. 10.3390/nano1510075510.3390/nano15100755 ↗
22. 10.1021/nl047950t10.1021/nl047950t ↗
23. 10.1117/1.JBO.22.12.12171110.1117/1.JBO.22.12.121711 ↗
24. 10.1002/lsm.2009810.1002/lsm.20098 ↗
25. 10.1126/scitranslmed.30106110.1126/scitranslmed.301061 ↗
26. 10.1016/j.nano.2012.07.00310.1016/j.nano.2012.07.003 ↗
27. 10.1117/1.325866910.1117/1.3258669 ↗
28. 10.1038/nprot.2007.32610.1038/nprot.2007.326 ↗
29. 10.1364/OL.39.00201610.1364/OL.39.002016 ↗
30. 10.1364/OL.41.00025010.1364/OL.41.000250 ↗
31. 10.1364/BOE.9.00373110.1364/BOE.9.003731 ↗
32. 10.1364/AO.16.00077710.1364/AO.16.000777 ↗
33. Matsumura Y. · Cancer Res. · 1986 · 46 · 6387
34. 10.1016/j.drudis.2006.07.00510.1016/j.drudis.2006.07.005 ↗
35. 10.1364/BOE.4.00084210.1364/BOE.4.000842 ↗
36. 10.1038/srep4490910.1038/srep44909 ↗